|
 |
|
|||||||
|
|||||||||
© 2003 by the American Diabetes Association, Inc.
Letters: Observations |
Long-Term, Randomized Clinical Trial of Two Diets in the Metabolic Syndrome and Type 2 Diabetes
1 Department of Medicine, Baylor College of Medicine, Houston, Texas
2 Statistical Design and Analysis, Austin, Texas
3 Center for Collaborative and Interactive Technologies, Baylor College of Medicine, Houston, Texas
Address correspondence to Lynne W. Scott, MA, RD, Baylor College of Medicine, 6550 Fannin, Smith Tower 1271, Houston, TX 77030. E-mail: lscott{at}bcm.tmc.edu
The best dietary balance of fatty acids, protein, and carbohydrate in patients with both glucose and lipid metabolism disorders remains unclear (1). Substitution of carbohydrates for saturated fatty acids frequently leads to increased triglyceride and decreased HDL cholesterol (2), adverse effects not seen with increased dietary monounsaturated fatty acids (MUFAs) (3). Moderate hyperglycemia can contribute to increased turnover of protein, suggesting increased need for protein in type 2 diabetes (4).
Between January 2000 and February 2001, we randomized 35 patients with the metabolic syndrome or type 2 diabetes to the contemporary American Heart Association (AHA) diet (15% of calories from protein, 30% fat, and 15% MUFAs) or a diet higher in protein, total fat, and MUFAs (25, 40, and 22% of calories, respectively; HiPro-HiMono diet). Enrollment criteria for the 42-week trial were BMI 
25 kg/m2, elevated fasting glucose (6.1–6.9 mmol/l [110–125 mg/dl] for impaired fasting glucose and 6.9 mmol/l [126 mg/dl] for diabetes), calculated LDL cholesterol >2.8 mmol/l, and fasting triglyceride 1.7 mmol/l. (The trial preceded the National Cholesterol Education Program’s clinical definition of the metabolic syndrome.) These risk factors were also the trial end points.
Patients were given a scale to weigh portions and prepared their own food, with the exception of almonds, which were given to the HiPro-HiMono group to replace other primary sources of MUFAs during the last 24 weeks. All patients were taught their diet and to self-monitor food intake and weight by using password-protected web pages with individualized meal plans, menus, and messages from a dietitian.
Twelve patients withdrew within 6 weeks (because of inability to attend clinic, computer problems, and/or health reasons). An additional six patients had one to two missing observations during the follow-up period. Multilevel models were used to describe the dietary effects and permitted the use of all collected data in the statistical analyses, including incomplete cases. At 42 weeks, although trends in risk factors slightly favored the HiPro-HiMono diet, changes were not significantly different between the AHA and HiPro-HiMono groups for weight (-5.9 vs. -9.1 kg; P = 0.768), triglyceride (-0.8 vs. -1.1 mmol/l; P = 0.920), fasting glucose (-2.2 vs. -3.2 mmol/l; P = 0.153), and LDL cholesterol (0.23 vs. 0.18 mmol/l; P = 0.217). The preponderance of patients improved their glycemic control. At 42 weeks, glycemic control was normalized in all 10 patients with impaired fasting glucose; it was also normalized in 2 and reduced to impaired fasting glucose in 3 of 7 patients with diabetes. Food record analyses to evaluate compliance showed that changes from the baseline diets to assigned levels of carbohydrate and total, saturated, and monounsaturated fats were significantly different between the groups, in keeping with different dietary goals. In a similar study (5), with slightly different diets, subjects at the end of 18 months were consuming diets of similar composition.
Our long-term study, enabled by our Internet Management System, was limited by small sample size. The power to detect a 10% difference between groups at 
= 0.05 with the observed SDs was <18% for LDL cholesterol, triglyceride, and fasting glucose. Weight loss was a potential confounding factor in the analyses. Nevertheless, the study’s trends support the hypothesis that a diet high in protein and MUFAs may be advantageous in correcting glucose and lipid metabolism abnormalities. Large, randomized, multicenter trials are needed.
Acknowledgments
Supported by National Institutes of Health Grant M01 RR00188 and grants from the Cattlemen’s Beef Board, the National Cattlemen’s Beef Association, the National Pork Producer’s Council, and the Almond Board of California.
References
- Grundy SM, Abate N, Chandalia M: Diet composition and the metabolic syndrome: what is the optimal fat intake? Am J Med 113 (Suppl 9B):25S–29S, 2002
- Turley ML, Skeaff CM, Mann JI, Cox B: The effect of a low-fat, high-carbohydrate diet on serum high density lipoprotein cholesterol and triglyceride. Eur J Clin Nutr 52:728–732, 1998[Medline]
- Garg A: High-monounsaturated-fat diets for patients with diabetes mellitus: a meta-analysis. Am J Clin Nutr 67 (Suppl.):577S–582S, 1998[Abstract]
- Gougeon R, Pencharz PB, Marliss EB: Effect of NIDDM on the kinetics of whole-body protein metabolism. Diabetes 43:318–328, 1994[Abstract]
- Milne MM, Mann JI, Chisholm AW, Williams SM: Long-term comparison of three dietary prescriptions in the treatment of NIDDM. Diabetes Care 17:74–80, 1994[Abstract]
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  D. J. A. Jenkins, F. B. Hu, L. C. Tapsell, A. R. Josse, and C. W. C. Kendall Possible Benefit of Nuts in Type 2 Diabetes J. Nutr., September 1, 2008; 138(9): 1752S - 1756S. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |